# Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

> **NCT05701436** · PHASE3 · UNKNOWN · sponsor: **Zhujiang Hospital** · enrollment: 144 (estimated)

## Conditions studied

- Liver, Cancer of, Primary Resectable

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Doxorubicin
- **DRUG:** Lobaplatin
- **DRUG:** Cisplatin
- **DRUG:** Oxaliplatin, Leucovorin, fluorouracil
- **DRUG:** Lobaplatin, Raltitrexed

## Key facts

- **NCT ID:** NCT05701436
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701436, "Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05701436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*